A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Clinical trial NCT07076121 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07076121
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-23
- Primary completion
- 2029-05-03
- Enrollment
- 470
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.